The Technical Analyst
Zynerba Pharmaceuticals [ZYNE]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Zynerba Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.36% $1.300
America/New_York / 10 okt 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70.12 mill |
| EPS: | -0.790 |
| P/E: | -1.646 |
| Earnings Date: | Nov 12, 2023 |
| SharesOutstanding: | 53.94 mill |
| Avg Daily Volume: | 1.043 mill |
| RATING 2023-10-13 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.646 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.646 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.260 - 1.340 ( +/- 3.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-10 | Jones Kenneth T | Buy | 30 000 | Common Stock |
| 2023-10-10 | Jones Kenneth T | Sell | 40 520 | Common Stock |
| 2023-10-10 | Jones Kenneth T | Sell | 75 000 | Common Stock |
| 2023-10-10 | Jones Kenneth T | Sell | 21 250 | Stock Option (Right to Buy) |
| 2023-10-10 | Stephenson Pamela | Sell | 27 954 | Common Stock |
| INSIDER POWER |
|---|
| -52.67 |
| Last 100 transactions |
| Buy: 1 916 312 | Sell: 5 402 740 |
Forecast:
01:40 - $1.475
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.300 (2.36% ) |
| Volume | 0.862 mill |
| Avg. Vol. | 1.043 mill |
| % of Avg. Vol | 82.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZYNE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2023-10-11 08:00:00 - Press Release
Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals And Expands Pipeline
New product in development diversifies portfolio to drive long-term growth innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs zygel™ in pivotal phase 3 trial for fragile x syndrome and has completed phase 2 proof-of-concept study in 22q11.2 deletion syndrome plymouth meeting, pa. , oct. 11, 2023 /prnewswire/ -- harmony biosciences holdings, inc. ("harmony") (nasdaq: hrmy), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of zynerba pharmaceuticals, inc. ("zynerba") (nasdaq: zyne).
2023-10-04 16:05:00 - Press Release
Important Information For Zynerba Pharmaceuticals Stockholders To Tender Shares For The Harmony Transaction: Process And Instructions
Devon, pa., oct. 04, 2023 (globe newswire) -- zynerba pharmaceuticals, inc. (nasdaq: zyne), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “offer”) by harmony biosciences holdings, inc. (“harmony”) and its wholly owned subsidiary, xylophone acquisition corp. (“purchaser”), to purchase all outstanding shares of zynerba common stock. the zynerba board of directors unanimously recommends that zynerba stockholders tender their shares pursuant to the offer.
2023-09-29 09:00:00 - Press Release
Zynerba Pharmaceuticals Stockholders Reminded To Tender Shares Before 5:00 Pm New York City Time, On Tuesday October 10, 2023
Devon, pa., sept. 29, 2023 (globe newswire) -- zynerba pharmaceuticals, inc. (nasdaq: zyne), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by harmony biosciences holdings, inc. (“harmony”).
2023-09-27 08:00:00 - Press Release
Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Plymouth meeting, pa. , sept. 27, 2023 /prnewswire/ -- in connection with the previously announced merger agreement, harmony biosciences holdings, inc. ("harmony") (nasdaq: hrmy), today announced that xylophone acquisition corp., a wholly owned subsidiary of harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of zynerba pharmaceuticals, inc. ("zynerba") (nasdaq: zyne) to 5:00 p.m.
2023-09-14 16:15:00 - Press Release
Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial In 22q11.2 Deletion Syndrome At The Society For The Study Of Behavioural Phenotypes (ssbp) 25th International Research Symposium
Zygel™ (zyn002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in inspire, a phase 2 trial with zygel in children and adolescents with 22q11.2 deletion syndrome (22q) zygel™ (zyn002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in inspire, a phase 2 trial with zygel in children and adolescents with 22q11.2 deletion syndrome (22q)
Latest News
2023-10-13 12:52:16 - The Motley Fool
Why Shares of Harmony Bioscience Are Falling on Friday
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year.
2023-08-14 13:52:59 - InvestorPlace
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday following an announcement early this morning of a buyout. Specifically, Harmony Biosciences (NASDAQ: HRMY ) — which focuses on innovative therapies for patients with rare neurological diseases — will acquire Zynerba.
2023-08-14 09:29:21 - Proactive Investors
Zynerba Pharma stock rockets on premium priced Harmony deal
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed three-times higher as investors are set to pocket a bumper payday as Harmony Biosciences (NASDAQ:HRMY) agreed to buy the cannabinoid therapies company for US$200 million. Harmony is to pay US$60 million, US$1.1059 per share, in cash cash upfront plus up to US$140 million in contingent future payments tied to clinical, regulatory and sales milestones.
2023-08-14 09:18:00 - Market Watch
Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal worth up to $200 million. Harmony, which specializes in therapies for rare neurological diseases, said it would acquire all outstanding shares of Zynerba for $1.1059 per share in cash, or $60 million in the aggregate, with potential additional payments of up to $140 million based on achievement of certain clinical, regulatory and sales milestones.
2023-06-29 13:39:41 - Zacks Investment Research
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-06-20 07:00:00 - GlobeNewsWire
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023.
2023-03-07 07:00:00 - GlobeNewsWire
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings.
2023-03-01 07:00:00 - GlobeNewsWire
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass.
2023-01-09 09:02:17 - Zacks Investment Research
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
2022-12-21 07:46:06 - Proactive Investors
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome (FXS). The pharma group said factors including the so-called 'Tripledemic' (high rates of respiratory syncytial virus (RSV), influenza and COVID-19) had led to higher-than-expected cancellations of initial screening visits at the trial's investigational centers, leading to slower-than-anticipated enrollment.